ID   PGFRB_HUMAN             Reviewed;        1106 AA.
AC   P09619; Q8N5L4;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   02-NOV-2010, entry version 142.
DE   RecName: Full=Beta-type platelet-derived growth factor receptor;
DE            Short=PDGF-R-beta;
DE            EC=2.7.10.1;
DE   AltName: Full=CD140 antigen-like family member B;
DE   AltName: CD_antigen=CD140b;
DE   Flags: Precursor;
GN   Name=PDGFRB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=88217915; PubMed=2835772; DOI=10.1073/pnas.85.10.3435;
RA   Gronwald R.G.K., Grant F.J., Haldeman B.A., Hart C.E., O'Hara P.J.,
RA   Hagen F.S., Ross R., Bowen-Pope D.F., Murray M.J.;
RT   "Cloning and expression of a cDNA coding for the human platelet-
RT   derived growth factor receptor: evidence for more than one receptor
RT   class.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3435-3439(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=89096941; PubMed=2850496;
RA   Claesson-Welsh L., Eriksson A., Moren A., Severinsson L., Ek B.,
RA   Oestman A., Betsholtz C., Heldin C.-H.;
RT   "cDNA cloning and expression of a human platelet-derived growth factor
RT   (PDGF) receptor specific for B-chain-containing PDGF molecules.";
RL   Mol. Cell. Biol. 8:3476-3486(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT PHE-180.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 548-569.
RX   MEDLINE=97429921; PubMed=9285559; DOI=10.1038/sj.onc.1201267;
RA   Chi K.D., McPhee R.A., Wagner A.S., Dietz J.J., Pantazis P.,
RA   Goustin A.S.;
RT   "Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-
RT   I-infected T-cells results in a novel tyrosine kinase product with
RT   transforming activity.";
RL   Oncogene 15:1051-1057(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1046-1106.
RX   MEDLINE=89028677; PubMed=2846185; DOI=10.1016/0092-8674(88)90224-3;
RA   Roberts W.M., Look A.T., Roussel M.F., Sherr C.J.;
RT   "Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor
RT   genes.";
RL   Cell 55:655-661(1988).
RN   [6]
RP   PROTEIN SEQUENCE OF 33-47.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [7]
RP   PHOSPHORYLATION AT TYR-751 AND TYR-857.
RX   MEDLINE=89376563; PubMed=2550144; DOI=10.1016/0092-8674(89)90510-2;
RA   Kazlauskas A., Cooper J.A.;
RT   "Autophosphorylation of the PDGF receptor in the kinase insert region
RT   regulates interactions with cell proteins.";
RL   Cell 58:1121-1133(1989).
RN   [8]
RP   INTERACTION WITH SHB.
RX   MEDLINE=94134414; PubMed=8302579;
RA   Welsh M., Mares J., Karlsson T., Lavergne C., Breant B.,
RA   Claesson-Welsh L.;
RT   "Shb is a ubiquitously expressed Src homology 2 protein.";
RL   Oncogene 9:19-27(1994).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIP11.
RX   MEDLINE=98043615; PubMed=9373237;
RA   Abe A., Emi N., Tanimoto M., Terasaki H., Marunouchi T., Saito H.;
RT   "Fusion of the platelet-derived growth factor receptor beta to a novel
RT   gene CEV14 in acute myelogenous leukemia after clonal evolution.";
RL   Blood 90:4271-4277(1997).
RN   [10]
RP   INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-579; TYR-581; TYR-716;
RP   TYR-740; TYR-751; TYR-771; TYR-857; TYR-1009 AND TYR-1021.
RX   PubMed=10454568;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [11]
RP   INTERACTION WITH APS.
RX   MEDLINE=99142932; PubMed=9989826; DOI=10.1038/sj.onc.1202326;
RA   Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S.,
RA   Sasaki A., Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.;
RT   "APS, an adaptor protein containing PH and SH2 domains, is associated
RT   with the PDGF receptor and c-Cbl and inhibits PDGF-induced
RT   mitogenesis.";
RL   Oncogene 18:759-767(1999).
RN   [12]
RP   INTERACTION WITH PIK3C2B.
RX   PubMed=10805725; DOI=10.1128/MCB.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of
RT   activated polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [13]
RP   FUNCTION AS A RECEPTOR FOR PDGFD.
RX   MEDLINE=21231379; PubMed=11331881; DOI=10.1038/35074588;
RA   Bergsten E., Uutela M., Li X., Pietras K., Oestman A., Heldin C.-H.,
RA   Alitalo K., Eriksson U.;
RT   "PDGF-D is a specific, protease-activated ligand for the PDGF beta-
RT   receptor.";
RL   Nat. Cell Biol. 3:512-516(2001).
RN   [14]
RP   CHROMOSOMAL TRANSLOCATION WITH ETV6.
RX   PubMed=12181402; DOI=10.1056/NEJMoa020150;
RA   Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J.,
RA   Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E.,
RA   Dimitrijevic S., Mahon F.-X., Marin D., Nikolova Z., Olavarria E.,
RA   Silberman S., Schultheis B., Cross N.C.P., Goldman J.M.;
RT   "Response to imatinib mesylate in patients with chronic
RT   myeloproliferative diseases with rearrangements of the platelet-
RT   derived growth factor receptor beta.";
RL   N. Engl. J. Med. 347:481-487(2002).
RN   [15]
RP   CHROMOSOMAL TRANSLOCATION WITH PDE4DIP.
RX   PubMed=12907457; DOI=10.1182/blood-2003-04-1150;
RA   Wilkinson K., Velloso E.R.P., Lopes L.F., Lee C., Aster J.C.,
RA   Shipp M.A., Aguiar R.C.T.;
RT   "Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder
RT   associated with eosinophilia: involvement of PDGFRB and response to
RT   imatinib.";
RL   Blood 102:4187-4190(2003).
RN   [16]
RP   CHROMOSOMAL TRANSLOCATION WITH SPECC1.
RX   PubMed=15087372; DOI=10.1158/0008-5472.CAN-03-4026;
RA   Morerio C., Acquila M., Rosanda C., Rapella A., Dufour C.,
RA   Locatelli F., Maserati E., Pasquali F., Panarello C.;
RT   "HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile
RT   myelomonocytic leukemia with t(5;17)(q33;p11.2).";
RL   Cancer Res. 64:2649-2651(2004).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 751-755 IN COMPLEX WITH
RP   PIK3R1, AND COMPARISON WITH NMR ANALYSIS.
RX   MEDLINE=21450159; PubMed=11567151; DOI=10.1107/S0907444901012434;
RA   Pauptit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A.,
RA   Rowsell S., Murshudov G.N.;
RT   "NMR trial models: experiences with the colicin immunity protein Im7
RT   and the p85alpha C-terminal SH2-peptide complex.";
RL   Acta Crystallogr. D 57:1397-1404(2001).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1102-1106 IN COMPLEX WITH
RP   SLC9A3R1 AND PDGFRA.
RX   MEDLINE=22013966; PubMed=11882663; DOI=10.1074/jbc.M201507200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural determinants of the Na+/H+ exchanger regulatory factor
RT   interaction with the beta 2 adrenergic and platelet-derived growth
RT   factor receptors.";
RL   J. Biol. Chem. 277:18973-18978(2002).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-29; LYS-282; LYS-485; HIS-589;
RP   TYR-718 AND ILE-882.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor that binds specifically to PDGFB and PDGFD and
CC       has a tyrosine-protein kinase activity. Phosphorylates Tyr
CC       residues at the C-terminus of PTPN11 creating a binding site for
CC       the SH2 domain of GRB2.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Homodimer, and heterodimer with PDGFRA. Interacts with
CC       APS. The autophosphorylated form interacts directly with SHB and
CC       with PIK3C2B, maybe indirectly. Interacts with GRB10.
CC   -!- INTERACTION:
CC       P01127:PDGFB; NbExp=1; IntAct=EBI-641237, EBI-1554925;
CC       O00750:PIK3C2B; NbExp=1; IntAct=EBI-641237, EBI-641107;
CC       P18031:PTPN1; NbExp=1; IntAct=EBI-641237, EBI-968788;
CC       Q05209:PTPN12; NbExp=1; IntAct=EBI-641237, EBI-2266035;
CC       Q9Y2R2:PTPN22; NbExp=1; IntAct=EBI-641237, EBI-1211241;
CC       P29350:PTPN6; NbExp=1; IntAct=EBI-641237, EBI-78260;
CC       P23467:PTPRB; NbExp=1; IntAct=EBI-641237, EBI-1265766;
CC       P08575:PTPRC; NbExp=1; IntAct=EBI-641237, EBI-1341;
CC       P23469:PTPRE; NbExp=1; IntAct=EBI-641237, EBI-2258070;
CC       P23470:PTPRG; NbExp=1; IntAct=EBI-641237, EBI-2258115;
CC       Q12913:PTPRJ; NbExp=1; IntAct=EBI-641237, EBI-2264500;
CC       Q15262:PTPRK; NbExp=1; IntAct=EBI-641237, EBI-474052;
CC       Q16827:PTPRO; NbExp=1; IntAct=EBI-641237, EBI-723739;
CC       Q15256:PTPRR; NbExp=1; IntAct=EBI-641237, EBI-2265659;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- DISEASE: Note=A chromosomal aberration involving PDGFRB is found
CC       in a form of chronic myelomonocytic leukemia (CMML). Translocation
CC       t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal
CC       clonal myeloid proliferation and by progression to acute
CC       myelogenous leukemia (AML).
CC   -!- DISEASE: Note=A chromosomal aberration involving PDGFRB may be a
CC       cause of acute myelogenous leukemia. Translocation
CC       t(5;14)(q33;q32) with TRIP11. The fusion protein may be involved
CC       in clonal evolution of leukemia and eosinophilia.
CC   -!- DISEASE: Note=A chromosomal aberration involving PDGFRB may be a
CC       cause of juvenile myelomonocytic leukemia. Translocation
CC       t(5;17)(q33;p11.2) with SPECC1.
CC   -!- DISEASE: Defects in PDGFRB are a cause of myeloproliferative
CC       disorder chronic with eosinophilia (MPE) [MIM:131440]. A
CC       hematologic disorder characterized by malignant eosinophils
CC       proliferation. Note=A chromosomal aberration involving PDGFRB is
CC       found in many instances of myeloproliferative disorder chronic
CC       with eosinophilia. Translocation t(5;12) with ETV6 on chromosome
CC       12 creating an PDGFRB-ETV6 fusion protein.
CC   -!- DISEASE: Note=A chromosomal aberration involving PDGFRB may be the
CC       cause of a myeloproliferative disorder (MBD) associated with
CC       eosinophilia. Translocation t(1;5)(q23;q33) that forms a PDE4DIP-
CC       PDGFRB fusion protein.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PDGFRBID21ch5q32.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03278; AAA60049.1; -; mRNA.
DR   EMBL; M21616; AAA36427.1; -; mRNA.
DR   EMBL; BC032224; AAH32224.1; -; mRNA.
DR   EMBL; U33172; AAC51675.1; -; Genomic_DNA.
DR   IPI; IPI00015902; -.
DR   PIR; A28206; PFHUGB.
DR   RefSeq; NP_002600.1; -.
DR   UniGene; Hs.509067; -.
DR   PDB; 1GQ5; X-ray; 2.20 A; A=1102-1106.
DR   PDB; 1H9O; X-ray; 1.79 A; B=751-755.
DR   PDB; 1LWP; Model; -; A=600-962.
DR   PDB; 3MJG; X-ray; 2.30 A; X/Y=33-314.
DR   PDBsum; 1GQ5; -.
DR   PDBsum; 1H9O; -.
DR   PDBsum; 1LWP; -.
DR   PDBsum; 3MJG; -.
DR   ProteinModelPortal; P09619; -.
DR   SMR; P09619; 35-521, 559-695, 560-962.
DR   DIP; DIP-558N; -.
DR   IntAct; P09619; 15.
DR   MINT; MINT-148093; -.
DR   STRING; P09619; -.
DR   PhosphoSite; P09619; -.
DR   PRIDE; P09619; -.
DR   Ensembl; ENST00000261799; ENSP00000261799; ENSG00000113721.
DR   GeneID; 5159; -.
DR   KEGG; hsa:5159; -.
DR   UCSC; uc003lro.1; human.
DR   CTD; 5159; -.
DR   GeneCards; GC05M149473; -.
DR   H-InvDB; HIX0024847; -.
DR   HGNC; HGNC:8804; PDGFRB.
DR   HPA; CAB003842; -.
DR   HPA; CAB018144; -.
DR   HPA; HPA028499; -.
DR   MIM; 131440; phenotype.
DR   MIM; 173410; gene.
DR   Orphanet; 98823; Chronic myelomonocytic leukemia.
DR   Orphanet; 3260; Idiopathic hypereosinophilic syndrome.
DR   Orphanet; 168950; Myeloid neoplasm associated with PDGFRB rearrangement.
DR   Orphanet; 86830; Unclassified chronic myeloproliferative disease.
DR   PharmGKB; PA33148; -.
DR   eggNOG; prNOG17402; -.
DR   HOGENOM; HBG445154; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P09619; -.
DR   OMA; GACTKGG; -.
DR   OrthoDB; EOG9VMJ1R; -.
DR   PhylomeDB; P09619; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; pdgfrbpathway; PDGFR-beta signaling pathway.
DR   Pathway_Interaction_DB; s1p_s1p1_pathway; S1P1 pathway.
DR   Pathway_Interaction_DB; s1p_s1p3_pathway; S1P3 pathway.
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Reactome; REACT_16888; Signaling by PDGF.
DR   DrugBank; DB00102; Becaplermin.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   NextBio; 19958; -.
DR   ArrayExpress; P09619; -.
DR   Bgee; P09619; -.
DR   CleanEx; HS_PDGFRB; -.
DR   Genevestigator; P09619; -.
DR   GermOnline; ENSG00000113721; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004992; F:platelet activating factor receptor activity; TAS:ProtInc.
DR   GO; GO:0005019; F:platelet-derived growth factor beta-recepto...; IDA:BHF-UCL.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor bin...; IPI:BHF-UCL.
DR   GO; GO:0005021; F:vascular endothelial growth factor receptor...; IEA:InterPro.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IDA:BHF-UCL.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR016243; Tyr_prot_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR020727; Tyr_prot_kinase_PDGF_rcpt_b.
DR   InterPro; IPR001824; Tyr_prot_kinase_rcpt_3_CS.
DR   InterPro; IPR009134; Tyr_prot_kinase_VEGFR_rcpt_N.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 4.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   PANTHER; PTHR23256:SF236; Tyr_prot_kinase_PDGF_rcpt_b; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   PRINTS; PR01832; VEGFRECEPTOR.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Chromosomal rearrangement;
KW   Complete proteome; Direct protein sequencing; Disulfide bond;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Receptor; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     32
FT   CHAIN        33   1106       Beta-type platelet-derived growth factor
FT                                receptor.
FT                                /FTId=PRO_0000016757.
FT   TOPO_DOM     33    531       Extracellular (Potential).
FT   TRANSMEM    532    556       Helical; (Potential).
FT   TOPO_DOM    557   1106       Cytoplasmic (Potential).
FT   DOMAIN       33    120       Ig-like C2-type 1.
FT   DOMAIN      129    210       Ig-like C2-type 2.
FT   DOMAIN      214    309       Ig-like C2-type 3.
FT   DOMAIN      331    403       Ig-like C2-type 4.
FT   DOMAIN      416    524       Ig-like C2-type 5.
FT   DOMAIN      600    962       Protein kinase.
FT   NP_BIND     606    614       ATP (By similarity).
FT   ACT_SITE    826    826       Proton acceptor (By similarity).
FT   BINDING     634    634       ATP (By similarity).
FT   SITE        527    528       Breakpoint for insertion to form PDE4DIP-
FT                                PDGFRB fusion protein.
FT   SITE        527    528       Breakpoint for translocation to form
FT                                TRIP11-PDGFRB.
FT   MOD_RES     751    751       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     857    857       Phosphotyrosine; by autocatalysis.
FT   CARBOHYD     45     45       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     89     89       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    103    103       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    215    215       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    230    230       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    292    292       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    307    307       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    354    354       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    371    371       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    468    468       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    479    479       N-linked (GlcNAc...) (Potential).
FT   DISULFID     54    100       Potential.
FT   DISULFID    149    190       Potential.
FT   DISULFID    235    291       Potential.
FT   DISULFID    436    508       Potential.
FT   VARIANT      29     29       I -> F (in dbSNP:rs17110944).
FT                                /FTId=VAR_034377.
FT   VARIANT     180    180       S -> F (in dbSNP:rs17853027).
FT                                /FTId=VAR_035125.
FT   VARIANT     282    282       E -> K (in dbSNP:rs34586048).
FT                                /FTId=VAR_042027.
FT   VARIANT     345    345       P -> S (in dbSNP:rs2229558).
FT                                /FTId=VAR_049717.
FT   VARIANT     485    485       E -> K (in dbSNP:rs41287110).
FT                                /FTId=VAR_042028.
FT   VARIANT     589    589       Y -> H (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042029.
FT   VARIANT     718    718       N -> Y (in dbSNP:rs35322465).
FT                                /FTId=VAR_042030.
FT   VARIANT     882    882       T -> I (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_042031.
FT   MUTAGEN     579    579       Y->F: No effect on GRB10-binding.
FT   MUTAGEN     581    581       Y->F: No effect on GRB10-binding.
FT   MUTAGEN     716    716       Y->F: No effect on GRB10-binding.
FT   MUTAGEN     740    740       Y->F: No effect on GRB10-binding.
FT   MUTAGEN     751    751       Y->F: No effect on GRB10-binding.
FT   MUTAGEN     771    771       Y->F: Loss of GRB10-binding.
FT   MUTAGEN     857    857       Y->F: No effect on GRB10-binding.
FT   MUTAGEN    1009   1009       Y->F: No effect on GRB10-binding.
FT   MUTAGEN    1021   1021       Y->F: No effect on GRB10-binding.
FT   CONFLICT    241    241       E -> D (in Ref. 2; AAA36427).
FT   STRAND      601    603
FT   STRAND      606    613
FT   STRAND      615    617
FT   STRAND      620    624
FT   HELIX       628    631
FT   STRAND      632    634
FT   HELIX       641    649
FT   STRAND      671    673
FT   STRAND      675    678
FT   STRAND      681    685
FT   HELIX       686    695
FT   STRAND      700    702
FT   STRAND      713    716
FT   STRAND      726    735
FT   STRAND      740    746
FT   TURN        747    749
FT   STRAND      750    757
FT   HELIX       761    766
FT   STRAND      775    779
FT   STRAND      781    783
FT   STRAND      785    788
FT   HELIX       800    820
FT   HELIX       829    831
FT   STRAND      832    834
FT   HELIX       836    838
FT   STRAND      840    842
FT   HELIX       847    850
FT   HELIX       855    858
FT   STRAND      862    865
FT   TURN        867    869
FT   HELIX       872    877
FT   HELIX       882    897
FT   TURN        898    900
FT   STRAND      903    907
FT   HELIX       910    919
FT   HELIX       931    940
FT   TURN        945    947
FT   HELIX       951    959
SQ   SEQUENCE   1106 AA;  123968 MW;  038C15E531D6E89D CRC64;
     MRLPGAMPAL ALKGELLLLS LLLLLEPQIS QGLVVTPPGP ELVLNVSSTF VLTCSGSAPV
     VWERMSQEPP QEMAKAQDGT FSSVLTLTNL TGLDTGEYFC THNDSRGLET DERKRLYIFV
     PDPTVGFLPN DAEELFIFLT EITEITIPCR VTDPQLVVTL HEKKGDVALP VPYDHQRGFS
     GIFEDRSYIC KTTIGDREVD SDAYYVYRLQ VSSINVSVNA VQTVVRQGEN ITLMCIVIGN
     EVVNFEWTYP RKESGRLVEP VTDFLLDMPY HIRSILHIPS AELEDSGTYT CNVTESVNDH
     QDEKAINITV VESGYVRLLG EVGTLQFAEL HRSRTLQVVF EAYPPPTVLW FKDNRTLGDS
     SAGEIALSTR NVSETRYVSE LTLVRVKVAE AGHYTMRAFH EDAEVQLSFQ LQINVPVRVL
     ELSESHPDSG EQTVRCRGRG MPQPNIIWSA CRDLKRCPRE LPPTLLGNSS EEESQLETNV
     TYWEEEQEFE VVSTLRLQHV DRPLSVRCTL RNAVGQDTQE VIVVPHSLPF KVVVISAILA
     LVVLTIISLI ILIMLWQKKP RYEIRWKVIE SVSSDGHEYI YVDPMQLPYD STWELPRDQL
     VLGRTLGSGA FGQVVEATAH GLSHSQATMK VAVKMLKSTA RSSEKQALMS ELKIMSHLGP
     HLNVVNLLGA CTKGGPIYII TEYCRYGDLV DYLHRNKHTF LQHHSDKRRP PSAELYSNAL
     PVGLPLPSHV SLTGESDGGY MDMSKDESVD YVPMLDMKGD VKYADIESSN YMAPYDNYVP
     SAPERTCRAT LINESPVLSY MDLVGFSYQV ANGMEFLASK NCVHRDLAAR NVLICEGKLV
     KICDFGLARD IMRDSNYISK GSTFLPLKWM APESIFNSLY TTLSDVWSFG ILLWEIFTLG
     GTPYPELPMN EQFYNAIKRG YRMAQPAHAS DEIYEIMQKC WEEKFEIRPP FSQLVLLLER
     LLGEGYKKKY QQVDEEFLRS DHPAILRSQA RLPGFHGLRS PLDTSSVLYT AVQPNEGDND
     YIIPLPDPKP EVADEGPLEG SPSLASSTLN EVNTSSTISC DSPLEPQDEP EPEPQLELQV
     EPEPELEQLP DSGCPAPRAE AEDSFL
//
